Vaccines against COVID-19 were developed, approved, and distributed at an
unprecedented speed during the coronavirus disease pandemic. These vaccines have …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …

Background Two vaccine candidates for coronavirus disease 2019 (Covid-19) have been
announced by Pfizer-BioNTech and Moderna with above 90% efficacy. The efficacy of each …

Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection has been present since its outbreak in 2019. Despite global efforts to fully halt its …

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data.
We wanted to compare risks and benefits. Method: We calculated the number needed to …

In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was
mentioned as one of the main exclusion criteria. In the absence of clinical trials …

Vaccines are vital to control the Coronavirus disease 2019 (COVID-19) pandemic, but the
pressure to quickly move from research to implementation in the context of a pandemic crisis …

This article provides a systematic assessment of the efficacy, risks, and methodological
quality of evidence from five major publicly available vaccine trials. Results from Pfizer …

Introduction After its emergence in China, the COVID‐19 pandemic has spread rapidly
around the world, affecting all of our lives. Over the past few months, different vaccines have …